Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q37118356

about

Clinical immunologic approaches for the treatment of Alzheimer's disease Immunotherapy as treatment for Alzheimer’s disease Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model Active and passive immunotherapy for neurodegenerative disorders Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice The immunotherapy of Alzheimer's disease Microglial responses to amyloid beta peptide opsonization and indomethacin treatment.Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.Revolutionizing Alzheimer's disease and clinical trials through biomarkers Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Engineering humoral immunity as prophylaxis or therapy Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Immunotherapy for Alzheimer's disease: hoops and hurdles Diverse molecular targets for therapeutic strategies in Alzheimer's disease New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms Tau-targeted treatment strategies in Alzheimer's disease Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease Molecular basis for passive immunotherapy of Alzheimer's disease Stabilization of a -hairpin in monomeric Alzheimer's amyloid- peptide inhibits amyloid formation Structures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,His-tag binding by antibody C706 mimics β-amyloid recognition Immunotherapeutic approaches for Alzheimer's disease Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease Prion peptide uptake in microglial cells--the effect of naturally occurring autoantibodies against prion protein Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms Effects of NK-4 in a transgenic mouse model of Alzheimer's disease An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

P2860

Q22241380-44E7FB2A-8900-45F4-84AD-B2DB021C1858 Q22241491-A3BFF315-BE72-4417-886C-CC5C57E40691 Q24534813-D8247C4B-55D2-4F33-BD17-AD0BEB6863E7 Q24603976-712BE1D8-F762-4ED3-9E78-E49FDF276DDA Q24608911-2277D07B-2A48-4EC7-BADC-B592D3D567BF Q24657879-E4539490-992F-4074-968E-E03390F7B1F9 Q24676179-9AC6D8B3-0080-4F21-BE26-3A3555246A4D Q24679444-A246E7EC-B991-4218-80ED-0326BBDB7070 Q24791704-9A04610F-CD70-4B48-8C60-967AE86E9ABE Q24799252-15A3E576-1312-4D01-8B94-9BB82804A316 Q24804900-9A298DAA-9AB6-40FE-81EC-043E01E3DC6E Q24811635-F1A9C98F-A587-4432-91DB-F10FC2B03C93 Q25256570-B38AC67C-A94C-4871-84FF-E4EB33FAE949 Q26744882-562B7DB4-FC83-4948-BC43-633C22500C62 Q26752508-D72F19EC-A04C-4C6E-8975-CB3DA471AF20 Q26784569-E4F29A02-094C-447F-90FC-4D471D714E8C Q26800101-39BBA0E4-BA38-4425-BAFF-DE548A9A9BB5 Q26822002-2B2E187C-609E-4FEF-AF9B-8F528030C524 Q26823877-779964ED-6EAA-4CFD-B0C9-EFD9FD9E03E7 Q26827193-030F549B-FE8F-4E6F-8185-283850BFEE8E Q26866006-12612182-8EB8-4097-8924-86A171E174A8 Q27001177-10C34917-AA37-4C91-A644-A87651D9F913 Q27023429-75FAA4DC-9DE6-4522-944D-F7C11F73D17B Q27023953-022CF261-39FA-4CA8-AB7F-53D632379DC3 Q27320084-FAAE10EC-B503-48AA-8F05-7C86F8335884 Q27349010-C27CFF0C-486C-4875-A4F5-A998A3EB0049 Q27648521-B015E992-F63B-45F8-81F0-F1E35177A232 Q27650192-0ADB1BF1-1A13-47C6-9169-BD885CCD965B Q27655072-C4E95E11-42AD-4454-88BC-E5E5F58021D3 Q27664463-CA59BDD2-8F90-426D-B99F-11582A14064B Q28081278-3FBC1E29-23F5-4024-BF16-F6ED028A10CC Q28504767-C6DB552C-08CF-402C-B162-29EB3C708CF6 Q28534389-9A45FA03-389F-43BF-97A9-ED53920A673B Q28570444-DE468ED0-4B5E-4EA6-8647-A874B640650F Q28655482-A3141DE9-8483-470A-A76D-8C4748C4AE34 Q28680809-19A1C67A-4FA0-4BBD-9556-9AF26B744BF6 Q28740342-E1887628-E9A7-44BA-99C8-ADCC3F6EFC75 Q30316057-1418B723-167E-437D-AC55-D5A254911717 Q30478932-8E9FB830-32A5-4127-A744-8D8EAB39E018 Q30486176-F41F4254-C08F-42D2-A8EC-73FB5BF18308

P2860

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q37118356

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 July 2001

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@en

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@nl

type

label

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@en

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@nl

prefLabel

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@en

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@nl

P1433

Q37118356-EC1D6301-53A3-45F3-ACEE-DE47DC096B86

P1476

Q37118356-19AFA6F7-65BF-4804-AA9B-163AC08E921B

P2093

Q37118356-01B7EA79-A98E-4747-8664-23BFF516D80B

Q37118356-3C26D25E-AC58-4F56-8796-C95F714926BF

Q37118356-900EF385-89A4-446D-9954-8F23984459D4

Q37118356-915FED0B-AFD9-478D-861A-82E35283E0C7

Q37118356-BEE5E11C-508C-422D-93AA-711C9831FA66

P2860

Q37118356-08CEA4D4-0995-4515-977A-2A7CC5A8C5B6

Q37118356-0AC07E43-C5BB-4888-A091-5943C8EA26D2

Q37118356-0BF2F644-1328-4E11-8B63-EC8F8CB56F46

Q37118356-10187DC0-5BD6-4664-A492-262999B86AFD

Q37118356-131950BD-F8A0-402D-9B18-FF6A8A05F463

Q37118356-1CA443A7-3188-4416-B4F5-843362B39318

Q37118356-24B6D7BA-34FD-4A58-9241-9EB236808914

Q37118356-339BB81E-C1C8-41FC-88FB-1464AE766F2A

Q37118356-3A2AF313-E4F7-4644-9DA0-F2EC3CCC4A99

Q37118356-44D084F3-4495-4638-9330-06F8D5A81D1F

P304

Q37118356-6FB576BC-4431-47D4-8959-C75C2F7C68C9

P31

Q37118356-B610AD76-FD27-4C51-9435-72414FB1E0C6

P356

Q37118356-4FD45D35-63F8-4E3C-87DC-18E68F828940

P407

Q37118356-7A11BF83-9A1F-4143-A995-D37B047C3F73

P433

Q37118356-246F5AA4-860E-4743-A854-608D61CCCD64

P478

Q37118356-7497144F-D8C8-40A8-AD6B-18AAF55192FE

P50

Q37118356-E329DD4A-E3C5-4171-B64C-F6832ED4A57C

P577

Q37118356-64B36691-0443-41A2-B0E1-3B0D22F14FB3

P5875

Q37118356-1436BA23-A474-4457-BA12-B60AE0E82D22

P698

Q37118356-E2EEF211-DBD1-42EF-9679-0BD5DB7B385D

P921

Q37118356-3EF9BF3F-12BE-4101-9C01-2A10B6F8282C

Q37118356-95F2AAF1-20BC-4402-9389-8178DFB14736

P932

Q37118356-FDAF6511-D73C-41E3-9967-5C1B9BF843BC

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Peripheral anti-A beta antibod ...... model of Alzheimer's disease.

@en

P2093

Bales KR

http://www.w3.org/2001/XMLSchema#string

Cummins DJ

http://www.w3.org/2001/XMLSchema#string

DeMattos RB

http://www.w3.org/2001/XMLSchema#string

Dodart JC

http://www.w3.org/2001/XMLSchema#string

Paul SM

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Two homologous genes causing early-onset familial Alzheimer's disease

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease.

Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

The role of presenilins in Alzheimer's disease.

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

P304

8850-8855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.151261398

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

P577

2001-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11901908

http://www.w3.org/2001/XMLSchema#string

P698

11438712

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

37524

http://www.w3.org/2001/XMLSchema#string